Home » Newsletters » BioWorld Science

BioWorld Science

June 22, 2007

View Archived Issues

Preclinical and clinical studies on Rebif(R) new formulation

Recent patents disclose new agents for depression, anxiety, psychosis and sleep disorders

Novel agents for treating endocrine-related disorders disclosed in recent patent literature

New therapeutic agents for respiratory and allergic disorders disclosed in recent patents

Novartis invests in Adenosine Therapeutics

Health Canada approves once-daily tramadol

Merck Serono and Ambrx collaborate on growth hormone products

OSI Pharmaceuticals begins phase I trials of OSI-906 for tumors

Recent Janssen and Pfizer patents describe novel analgesic agents

Rylomine significantly reduces postsurgical orthopedic pain

Interim findings for AVN-944 in hematologic malignancies

Kaken and Sunstar sign agreement for bFGF dental product development

NOP receptor antagonist improves parkinsonian-related motor dysfunction

New preclinical data on short-acting sedative CNS-7056

Liraglutide provides better glucose control than insulin glargine in phase III study

Phosphagenics delivery technology shows promise in dermatological fields

EULAR 2007: Studies of certolizumab pegol in rheumatoid arthritis

ARRY-797 meets endpoints in phase I study

ZymoGenetics and Bayer collaborate in global development of rThrombin

FDA agrees on SPA for OxyADF phase III trial

Bayer Schering Pharma to license imaging agent from Avid

DeveloGen grants worldwide exclusive license to Teva for protein kinase B

Resverlogix and Sun Health Research Institute collaborate for treatment of AD

Genzyme seeks FDA approval of Synvisc-One

Inulin polysulfate in vitro studies indicate potential to prevent osteoarthritis progression

Approvable letter for Risperdal sNDAs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...